Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NivoILP: Nivolumab with Isolated Limb Perfusion in Melanoma
NCT03685890Phase 2Recruiting
- Sponsor
- Region Västra Götaland
- Start
- Apr 2019
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of nivolumab in melanoma, sponsored by Region Västra Götaland. Started Apr 2019; status: recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03685890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03685890.